A study involving 66 patients with AML, MDS and CML who received a PR-1 vaccine demonstrated PR-1-specific T-cell response in 53% of patients [36]. This evidence concerns the gene TMEM37 and chronic myelogenous leukemia, BCR-ABL1 positive.